Issue I 2010

More
Achieves
Ranbaxy Global Consumer Everyone
Together
Healthcare (RGCH) -
Scaling New Heights...

With 14 successful brands

in the Indian market,

the RGCH story is only

getting bigger and brighter.

Editor's Desk 1
CEO’s Column 2
RGCH - Scaling New Heights 3
Frontline 7
Global Moves 9
Honours & Awards 15
Financial Update 18
Heart of Business 19
Happenings 21
Newstrack 23
01
Editor's Desk
 CEO’s Column
Dear Readers,

2009 has been a historic year for Ranbaxy. A year of great change, challenge; and opportunity.
It was also a year when most economies around the world did not grow, and currencies fluctuated significantly –
impacting business, pricing, liquidity, and profits. As you know, our business is very global.

During the year, there were some real significant events - the Company changed key ownership (from an Indian family,
to a Japanese corporate); we launched an important First to File (FTF) product, Valacyclovir, in the US; Paonta Sahib
plant was put under the Application Integrity Policy (AIP) by the USFDA, and our Gloversville facility received a warning
letter, and our anti malaria combination drug commenced Phase III clinical trials.

Despite the challenges, we remained focused and committed to our defined path. We continued to invest in the US and
India (in manufacturing and/or acquisition and /or resource).

On financials, we have surpassed our guidance, both on Revenue and Profit. The operational performance has
improved quarter on quarter. This has largely been possible due to our wide and deep business presence, across
developed and emerging markets; our timely decisions to change some specific country operating models; the value
of FTF opportunities in the US; and a comprehensive management of cost.

The integration within the Daiichi Sankyo (DS) group, through the Hybrid Business Model, is progressing well. This
unique and proactive Model has the potential to provide an excellent mix of innovative and affordable quality
medicine to people around the world. The scope is now wide and open – across geographies and functions. Some
implementation has already taken place – with a significant launch of a DS product, Olmesartan, in India, as Olvance.

Team Ranbaxy in 2009 has been exemplary – from the top management team that facilitated the smooth transition of
key ownership in May – a change of great magnitude in operation, sensitivity, and impact; to the US team that has
courageously and positively withstood some dark moments – and performed admirably again.

Our Toansa facility in India, and specific New Jersey facility in the US had successful FDA inspections; and all our
facilities, including Dewas and Paonta Sahib, had many successful inspections from regulators across the developed
world (outside of the US).

We thank all our stakeholders for their continued support, even in difficult times.

Going forward, quarter-on-quarter improving performance of 2009 has provided a good base and model, to build a
stronger 2010.

With Best Wishes

Atul Sobti
CEO & Managing Director

02
RGCH - Scaling New Heights
RGCH: A journey through the years

The Ranbaxy Global Consumer Healthcare (RGCH) story began in 2002 when Ranbaxy identified consumer
healthcare as its new business area and set up the OTC division. RGCH commenced its operations with the launch of
Pepfiz, Gesdyp and Garlic Pearls in the Indian market. The portfolios were strengthened with the inclusion of Revital.
RGCH today stands firm with 14 successful brands in the Indian market.
Though small, the business was viewed as being strategically important globally.
In 2005, Chericof brand was added to the kitty and in 2007, the division successfully managed the ethical to OTC
switch of an analgesic brand – Volini.
The challenge in the Indian context was to stride the overlapping space of FMCG marketing and Pharmaceutical
distribution, which was not an easy task. RGCH, therefore, chose a unique business platform, the rainbow coalition,
which is an integrated communication program targeted at doctors at one end and consumers at the other. In line with
this approach, the business reaches out to doctors to generate prescriptions and enhance doctor endorsements for
RGCH brands. Volini, for example, proudly acclaims to be India's No.1 prescribed brand in all its promotional
material. Simultaneously, giving the brand communication an emotional and human touch (like Revital's sign off line –
'Jiyo Jee Bhar Ke' – Live Life to the Fullest), helps in wide acceptability of the products.
The marketing efforts are supported by a strong sales and distribution system that includes a 150-strong sales force
and an outsourced medical marketing team. The products of RGCH reach 865 towns across India through more than
1000 OTC distributors.

Today, the division's flagship brand Revital, has crossed a turnover of Rs 1,000 million and is amongst India's top five
OTC brands. Volini, the topical analgesic brand, has crossed a turnover of Rs 600 million to become the fifth largest
and fastest growing brand among the top 10 pain rubefacients. The division has also launched Chyawan Active
(Sugar-free Chyawanprash), Revitalite (Protein Supplement) and Pepflux (Complete Antacid).

Ranbaxy reaches the Indian Soldier

In 2008, RGCH became the first Ranbaxy division to enter the Canteen Stores Department (CSD) of the Indian
Army through its flagship brands Revital and Volini. This unique distribution channel gives access to over 1.3
million homes and also helps Ranbaxy to distribute its products to far flung extremes of India like Leh, Andaman
Nicobar and North Eastern States, where distribution is otherwise cumbersome. In the first year of operations, the
business generated through the channel reached Rs 33 million. In 2009, this was supplemented with sampling
initiatives at the canteens to spread awareness for these products. It is envisaged that soon other brands of RGCH
will also find a place in the canteen stores.

03
 RGCH - Scaling New Heights
A look at the leading brands of RGCH:
REVITAL
Revital, a leading brand of RGCH, offers
a unique combination of Vitamins,
Minerals & Ginseng. Revital is one of the
most preferred brands of 'Daily Health
Supplement' among millions of
consumers in India, and one of the largest
selling brands in the Indian Pharma
Market.
The product was launched in early 90s as
a Vitamin Mineral supplement and soon
gained the trust of doctors and patients.
The brand witnessed steady growth over
the years as a product for recuperating
The making of a patients.
Mega Brand In 2002, Revital was moved to RGCH
division as its flagship brand. In order to
expand the usage of the product, it was
repositioned from a 'Recuperating Medicine' to a 'Daily Health Supplement', helping people live a fit and active life with
the brand promise ‘Jiyo Jee Bhar Ke' (Live Life To The Fullest). This change in positioning propelled the brand to newer
heights and in 2008 the brand sales doubled within three years.
The brand is continuously moving up the rank in the Indian Pharma Market and also features among the top 10 brands
today. It also appears amongst the top five brands in the Indian OTC market as per Nicholas Hall Yearbook, 2009.
The Revital success is largely attributed to an aggressive mix of first-of-its-kind in OTC market marketing and sales
initiatives, like the '21-day money back challenge', or the rural van promotion.
Taking the Revital promotion to the next level, Yuvraj Singh, the leading Indian cricketer, has been recently signed as
the brand ambassador for the product.

CHERICOF Chericof was transferred from Ranbaxy Stancare to RGCH in

2005. It is the flagship brand for the cough, cold, allergy and
herbal category at RGCH.
The cough segment is a large and fragmented category with
approximately 1,000 brands or variants available in the market.
Despite this, Chericof is ranked amongst the top few OTC
brands today. In fact, among the leading OTC cough brands –
Chericof has had the fastest growth rate for the past two years.
This has been made possible due to an aggressive trade activity
and seasonal media campaigns.
The communication for Chericof has been targeted at
housewives, identified by consumer research, as being the main
decision maker of the family for the purchase of cough syrups.
Chericof also has a strong heritage as being the children's
cough syrup; this fact was used in the initial communication
where the mother–child–family relationship was driven home in
the advertisements. Subsequently, in the recent past, the brand
has been reaching out to the entire family through its packaging
and other media.
Flagship brand for
The brand offers complete relief from cough and associated
Cough, Cold, Allergy
symptoms – blocked nose and sneezing, due to its unique triple
and Herbal Category impact cough formula. It reassures both housewives and families
that when it comes to cough, Chericof is the best caretaker.

04
RGCH - Scaling New Heights
VOLINI
Volini's journey started around 16 years back as an ethical brand for
topical pain relief, being promoted to Orthopaedics and other doctors. In
merely six years of its launch, it became the No. 1 prescribed brand and has
managed to retain its leadership position for the past 10 years.
In January 2007, Volini was switched to RGCH as an OTC product. At the
time, the brand analysis showed that though it had the best formulation and
pain relief properties, it lacked awareness. This indicated that building
'awareness-led trials' was the roadmap for growth.
Post multiple consumer researches, the brand was targeted at 30+ women
and positioned as the one, which delivers 'Real pain relief', basis its superior
formulation, compared to its main competitors. This was further supported
by the brand's quick absorption property and No.1 doctor prescribed status.
With a vision to make Volini affordable and competitive, two new smaller
packs of gel and spray were launched in 2007. In 2008, 1million
consumers were sampled out Volini through magazines and below-the-line
activities. These small packs, along with aggressive marketing investments,
have been successful in generating brand trials and driving the growth of
Fastest growing brand in
Volini. the Pain Relief category
Volini's marketing activities have made the brand grow from Rs 380 million in 2006 to a Rs 600 million brand, in less
than three years. In the Rs 8 billion Topical Pain Relief Indian Market (in MRP terms), Volini enjoys a 10% market share
and is ranked at No.5. It is the fastest growing brand amongst the top five players (which includes legacy brands) with
30% annual growth.
Volini has now been launched in a path-breaking single use sachet, priced at Rs 5. As any marketer in India would
know, LUPs (Low unit packs) have changed the rules of many categories through their affordability. RGCH too, wants
people in every nook and corner of the country, to experience the best pain relief and not compromise by using any
pain product, just because Volini is not affordable.

PEPFIZ
Launched in 1993, Pepfiz is an effervescent tablet that dissolves in water to
provide a tasty and bubbly drink, while offering immediate and total relief
from gas, heartburn and indigestion. Along with an anti-foaming agent
(Simethicone) that reduces bloating, discomfort and pain, caused by excess
gas in the stomach or intestinal tract, Pepfiz combines a strong mixture of
Digestive Enzymes that help digest the excess food, thereby, eliminating all
troubles such as gas, heartburn, burping, heaviness or any other discomfort
caused by undigested food. It has shown a sharp growth of nearly 30%, and
seems all set for a high growth trajectory. After years of stable sales, it is now
being targeted more at consumers than at doctors.
It is currently available in tasty orange and lemon flavours. Soon it will be
available in two more new and exciting flavours.
With consumer acceptability over the last years and success in all consumer
activation programs, a new brand message 'Acidity aur Badhazmi ka Kaam Relief from
Tamaam' (A relief from acidity and indigestion) has emerged, focused at Acidity and Indigestion
explaining the brand in a humorous manner.

CHYAWAN ACTIVE
In the beginning of 2008, RGCH entered the Chyawanprash segment, launching its sugar-free product under the
brand name Chyawan Active, an ayurvedic proprietary medicine, developed by Ranbaxy's Herbal Drug Research
team. The product has been manufactured using a novel formulation technology, which not only preserves all the
benefits of Classical ayurvedic chyawanprash, but also ensures great taste, without any added sugar.

05
 RGCH - Scaling New Heights
With lifestyle-related diseases on the rise, Chyawan Active offers an excellent
nutritional format for the entire family, especially to the health and calorie conscious
individuals, diabetics, obese and overweight people.
It is estimated that India has over 40 million diabetic patients, with 12% males and
16% females falling in the obese/overweight category. This phenomenon is
alarming and on the rise also among children and adolescents.
While, traditional chyawanprash contains almost 50-60% added sugar, Ranbaxy's
Chyawan Active does not have any added sugar, thereby, making it a healthy, low
calorie alternative for the existing consumers of chyawanprash. The chyawanprash
segment has a market size of around Rs 2,500 million and saw a growth of more
than l5% in terms of value and volume in 2007.
Chyawan Active launched a new advertising campaign highlighting the difference of
'No Added Sugar', thereby creating awareness among consumers of the product
being a healthier option to the category leader.
An excellent Nutritional
Product for the
entire Family
PEPFLUX
RGCH presents a new antacid – Pepflux, tagged as 'Acidity ka Best Upaay' (Best option for acidity),
in the second largest segment in the GI market. Pepflux is a unique antacid gel which can be truly
called 'the only complete antacid and gas relief formula in India'. It combines anti-reflux, antacid and
anti-flatulent agents in a powerful 5-in-1 formula. This makes it significantly more effective than other
antacids. Seconds after swallowing the tasty gel, the Alginic acid in the formula forms a raft in your
stomach, which prevents the excess acid from rising up to your throat or causing any kind of burning
sensations. The other ingredients then act on the acid and gas, removing them completely and
bringing you long lasting relief from acidity and gas. Pepflux is also sugar-free which makes it safe for
diabetics.
It is available in 'Ginger Mint' and 'Lemon Mint' flavours. It is tasty and gives a very cool and soothing
effect when swallowed. Unlike commonly available antacids which have a bad chalky taste and
lingering after taste, Pepflux has a smooth and silky texture. It is being accepted by doctors for acute A Complete
and chronic acidity, especially in cases where acid reflux is common. Antacid

REVITALITE
Ranbaxy launched its protein supplement under the brand name, Revitalite in
February 2009, marking its entry into the protein supplement market. Revitalite is
unique in its category as it offers the highest quantity and quality of protein in each
serving, compared to the existing brands. Revitalite is similar to world's largest
selling soy protein formulation and it comes at an affordable price. It can be mixed
with your favourite food or beverage.
Unlike other food components, protein is required to be consumed daily. Daily
adult requirement is approx. 50-60 gm and most of the available protein
supplement provide low quantity of protein. So one needs to take much higher
quantities and also several times a day. Revitalite delivers the highest quantity and
highest quality of protein in each serving, which helps to complete your daily
protein requirement.
Revitalite is preservative lactose and sugar-free. It is a soy-based protein powder,
Completes your daily ideal for lactose intolerant people. It can be added to any beverage like juice, milk,
lassi or any eatable while cooking. It is, therefore, ideal for young people on the
Protein Requirement move, children, men and women of all ages.
Ranbaxy has entered the protein supplement market, keeping in mind, the growing demand for high quality protein
supplements in the country. Revitalite offers an excellent option for the entire family. It will certainly address the problem
of protein deficiency, in people of all age groups.
Going forward, RGCH aims to scale new heights. It would contribute organically through its core brands like Revital,
Volini, Chericof and Pepfiz and also through the new product launches. Besides this, RGCH is also looking at
acquisition opportunities with possible OTC portfolios that will enable the company to expand its product basket and
business. RGCH would also look at some tactical brand acquisitions. Further, it will support the OTC business globally
by providing a rich product pipeline and marketing support, depending upon their requirements.

06
Frontline
THE ENERGY OF SYNERGY
Ranbaxy has established the "Synergy Office," which has the task of promoting synergies and thereby helping
maximize the opportunities for Ranbaxy and Daiichi Sankyo to expand their global operations.

SYNERGY OFFICE
AT
GURGAON,
INDIA

(Left to right) Mr Hiroyuki Okuzawa, Mr Varun Sood and Mr Eiichiro Sato

Implementing a Unique "Hybrid Management" Business Model

In a rapidly evolving global economy, everyday there is a new set of challenges-the search for treatments for
uncharted diseases, constant innovation and improvement of existing medicine, a quest for cost-effective alternatives
that make medicines more accessible, global reach, stringent regulations, and, above all, the need to maintain
profitability. The current scenario-that are forcing companies to "Think Differently" and "Think Ahead". The coming
together of Ranbaxy and Daiichi Sankyo is one such path-breaking confluence that catapults the new, empowered
entity to the status of the world's 15th largest pharmaceutical company. Individually, the two pharmaceutical giants are
formidable-one, India's largest Generics company, and the other, among the largest Innovator companies in Japan.
And now, this synchronization of proven, individual competencies in a unified, complementary platform has catalyzed
a high-octane thrust into a far-reaching transformational trajectory. This synergy of tested success mantras energizes
the combined business model manifold. It ushers in an expanded global footprint, a wider product portfolio, added
revenue streams, and better cost-competitiveness, while allowing both companies to optimize research and
manufacturing capabilities and much more.

Launch of the "Synergy Office”

To propel the synergy efforts further, Daiichi Sankyo and Ranbaxy established the "Synergy Office" in July 2009, at the
Ranbaxy headquarters in Gurgaon, India, with an intent to effectively operationalize the hybrid business model. The
office will provide direction to extract maximum future value from a matrix of countries, business lines, "back-end"
functions, and support services. The Synergy Office comprises three members - Mr Hiroyuki Okuzawa and
Mr Eiichiro Sato from Daiichi Sankyo and Mr Varun Sood from Ranbaxy.

Daiichi Sankyo and Ranbaxy teams exploring synergies in Romania

07
 Frontline
Leveraging the "Hybrid Business Model” The team will explore and evaluate possible synergies that can be drawn
from the coming together of Daiichi Sankyo and Ranbaxy and also carry
Front End the overall decision-making process under the guidance of the Senior
Opportunities: Leadership team of Daiichi Sankyo and Ranbaxy.
Launched More molecules
Africa, Japan, Olmesartan & in pipeline across
Korea, Mexico,
The three-member team reports to the Steering Committee, comprising
combo in India geographies
OTC Dr Tsutomu Une and Mr. Atul Sobti. The team is the single point of
contact for all synergy and related discussions and will evaluate such
Back End projects on a global scale. It will facilitate and manage these projects
R&D: Manufacturing: Logistics: and, in its current role, will also be responsible for the realization of
Discovery/ Dedicated Unit, US, EU agreed synergies within an agreed time frame by ensuring the
Development/ Japan Generics Services: successful execution of projects. Synergies between Daiichi Sankyo and
CMC IT/Procurement Ranbaxy are key to successfully implementing the hybrid business. Both
the companies have made good progress so far in identifying potential
synergy areas and continue to hold intensive discussions to effectively realize them.

Aiming to Sustain Growth Over the Long Term

The companies are evaluating collaboration opportunities and leveraging their strengths in various geographies and
markets as well as in areas of R&D, manufacturing, supply chain, and service/support functions, such as procurement,
IT, etc. The launch of "Olvance" by Ranbaxy in India and of "Evista" by Terapia Ranbaxy in Romania are examples of
synergies that will be leveraged jointly by the two companies to optimize sustainable growth in the long term. Most
recently, the two companies announced that the product portfolio of Daiichi Sankyo would be commercialized in
Mexico through a newly created marketing division within Ranbaxy Mexico S.A. de C.V., a subsidiary of Ranbaxy. This is
the first time in Latin America that Daiichi Sankyo and Ranbaxy are leveraging mutual synergies generated through the
Hybrid Business Model. Ranbaxy will also leverage its network in Africa and will be launching Olmesartan Medoxomil
(under brand name ‘Olvance’) in six African markets. Numerous other projects covering multiple markets and back-
end functions are in progress and shall be implemented in the near future.
in six African markets. Numerous other projects covering multiple markets and back-end functions are in progress and
shall be implemented in the near future.
The Synergy Office team will harness the respective capabilities of Daiichi Sankyo and Ranbaxy to unleash significant
progress for the companies.
Ranbaxy and Daiichi Sankyo share a common view on the nature of fundamental changes under way in the dynamics
of the industry. We strongly believe that the future environment can be successfully leveraged through the hybrid
model, combining the capabilities of an innovator and generics pharmaceutical company. Together with Daiichi
Sankyo, we will work towards optimizing growth opportunities in the global pharmaceutical landscape to create a
"Global Pharma Powerhouse".

DAIICHI SANKYO GROUP TO EXPAND ITS BUSINESS IN JAPAN THROUGH ESTABLISHMENT OF DAIICHI SANKYO ESPHA
In February 2010, Daiichi Sankyo and Ranbaxy announced that Daiichi Sankyo will establish Daiichi Sankyo Espha
Co., Ltd. (“Daiichi Sankyo Espha”) on April 1st, 2010. Daiichi Sankyo Espha will market generic drugs, as well as
Daiichi Sankyo’s products which have gained a well-established reputation in the market. Completing their
strategic alliance in November 2008 to form the unique Hybrid Business Model, Daiichi Sankyo and Ranbaxy have
been moving forward to fully leverage the Model. Leveraging Ranbaxy’s strengths, Daiichi Sankyo Espha will
expand its product pipeline and continuously realize stable supply.
“Daiichi Sankyo is dedicated to meeting the universal desire of patients to improve their health and better balance
their lives,” said Takashi Shoda, President & CEO of Daiichi Sankyo. “We believe that our understanding of the
Japanese market and local presence united with the global expertise of Ranbaxy in the generic arena will enable us
to achieve efficient and immediate entry into the generic market.”

Remarking on the development, Atul Sobti, CEO and Managing Director of Ranbaxy, said, “Daiichi Sankyo’s
leadership in the Japanese pharmaceutical market will guide us to further expand our business in Japan. Ranbaxy is
committed to bringing high quality, affordable medicines to doctors and patients across the world.”

08
Global Moves
EUROPE

ROMANIA - LAUNCH OF EVISTA

Daiichi Sankyo Company Limited and Ranbaxy Terapia SA, a subsidiary of Ranbaxy in Romania, will market the
Osteoporosis medication, Evista® in Romania. This is the first time in Europe, that Daiichi Sankyo and Ranbaxy are
leveraging synergies generated through the hybrid business model.

In 2006, Daiichi Sankyo acquired the marketing and distribution rights for Evista, an osteoporosis treatment, in six
European countries from Eli Lilly and Company. In 2008, Daiichi Sankyo acquired additional rights for the drug
covering all remaining countries in Europe, with the exception of Greece.

“The launch of Evista by Terapia Ranbaxy in Romania, marks our fi rst

international endeavour as a global partnership. Terapia Ranbaxy is a strong
player in Europe, and we will provide a unique platform to Daiichi Sankyo for the
launch of Evista and many more new products in the future.”
Mr Atul Sobti, CEO & MD, Ranbaxy
“We are delighted to announce this latest of the many synergies we will realise
through our cooperation with Ranbaxy. We continue to explore other
collaborations with Ranbaxy that will help optimise our growth.”
Mr Takashi Shoda, President & CEO, Daiichi Sankyo

USA

NEW JERSEY DEPARTMENT GIVES GRANT TO ohm LABS

Ohm Laboratories Inc. has been awarded a Customized Training

Grant for nearly US$ 70,000 by the New Jersey Department of
Labor and Workforce Development.
Ohm received the award letter from the Commissioner of the New
Jersey Department of Labor and Workforce Development,
notifying the approval for its application for financial assistance.
The agreement runs for a twelve-month period starting on August
24, 2009. Training must be completed no later than August 24,
2010 in order for Ohm to receive reimbursement funds for
employee training. Helen Owens, Associate Director, HR, will take
a lead role in overseeing the implementation of the grant.
According to Bernard Brothman, VP, HR, “It took a lot of work and
correspondence to pull all the information together in order to
apply for this grant. We are happy that Ohm has been accepted
for this award that will be used to fund the delivery of various
onsite training programs.”

RANBAXY GAINS WHO PRE-QUALIFICATION FOR INDINAVIR - 400MG ARV CAPSULES

The World Health Organisation, Geneva (WHO), has included Ranbaxy's Indinavir (as sulfate) - 400mg Anti Retroviral
(ARV) Capsule, in its pre-qualification list. With this new addition, Ranbaxy now has a total of 19 ARVs on the WHO pre-
qualification list.
Ranbaxy's ARVs, including the recently approved WHO pre-qualified products, are manufactured at the Company's
state-of-the-art manufacturing facilities.
Since 2001, Ranbaxy has been providing high quality ARV medicines, at affordable prices, in over 70 markets
worldwide, thereby facilitating access to patients afflicted by HIV/AIDS who might not otherwise have been able to gain
access to this therapy. The Company's ARVs have been used as mainstays in various large treatment programs, both
National and NGO/Institutional with good results. ARV medicines produced by Ranbaxy are used by over 5,00,000
patients worldwide, in various developing and underdeveloped countries.
09
 Global Moves
USA

VALACYCLOVIR LAUNCHED IN THE US MARKET

Ranbaxy Pharmaceuticals Inc, (RPI) introduced Valacyclovir

Hydrochloride, 500mg and 1g tablets on 25th November,
having previously been granted USFDA approval for these
oral dosage forms.
RPI, being the first to file and to successfully challenge the
Valacyclovir patents, is the first generic pharmaceutical
manufacturer entitled to offer an affordable alternative to the
brand, Valtrex tablets by GlaxoSmithKline.
Valacyclovir is an anti-viral agent which is indicated in a variety
of herpetic infections. Total market sales for Valacyclovir HCl
tablets were US$ 2.2 billion (IMS – MAT: September, 2009)
RPI will market the product under the RPI label that will be
manufactured at its US manufacturing facility - Ohm
Laboratories, New Brunswick, NJ. The product will be offered
immediately to all classes of trade on an allocated basis.

AUTHORISED GENERIC VERSION OF ROCALTROL® LAUNCHED

Ranbaxy Pharmaceuticals Inc. (RPI), has made an agreement with Validus Pharmaceuticals LLC (Validus) to market
and distribute an authorised generic version of Rocaltrol® (calcitriol) in both softgel capsules and an oral liquid
formulation.
Rocaltrol® is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in
patients with moderate to severe chronic renal failure not yet on dialysis, and in the management of hypocalcemia and
the resultant metabolic bone disease in patients undergoing chronic renal dialysis.
“This product represents an excellent commercial opportunity for Ranbaxy which will increase our visibility and
presence in the US healthcare system. We look forward to a long and prosperous partnership with Validus,” said Jim
Meehan, Vice President, Sales & Distribution, RPI.
Ranbaxy expects to be the only generic company offering all forms and strengths of generic Rocaltrol®.

USFDA APPROVAL TO MANUFACTURE AND MARKET GLYCOPYRROLATE TABLETS

Ranbaxy received final approval from the USFDA to

manufacture and market Glycopyrrolate Tablets USP, 1 mg
and 2 mg (reference listed drug Robinul® 1 mg and
Robinul® Forte Tablets, 2 mg, respectively, of Sciele
Pharma, Inc.) Glycopyrrolate Tablets are indicated for use
as adjunctive therapy in the treatment of peptic ulcer.
“We are pleased to receive this final approval for
Glycopyrrolate Tablets. The product formulation will be
launched in the Oct–Dec quarter to all classes of trade and
further expands the number of affordable generic product
formulations offered by RPI, that will be of benefit to
patients, healthcare professionals and the US healthcare
system,” said Mr Jim Meehan, Vice President, Sales &
Distribution, Ranbaxy Pharmaceuticals Inc.

10
Global Moves
LATAM

MEXICO - DAIICHI SANKYO TO LEVERAGE RANBAXY’S PRESENCE

In a synergistic partnership with Ranbaxy,

Daiichi Sankyo will commercialize its portfolio
in Mexico through a recently created marketing
division within Ranbaxy Mexico SA de CV
(a Ranbaxy subsidiary.) This is the first time in
Latin America, that Daiichi Sankyo and Ranbaxy
are leveraging mutual synergies generated
through the 'Hybrid Business Model'.
Remarking on the development, Mr Takashi
Shoda, President & CEO, Daiichi Sankyo, said,
“We are dedicated to realize various synergies
through our hybrid business model which
enables both companies to fully realize their
strengths. I am pleased to announce one of
such synergies - our commitment to directly introduce Daiichi Sankyo products in Mexico, leveraging Ranbaxy's strong
platform. I believe our products will offer an excellent therapy option to the doctors and patients in Mexico.”
Mr Atul Sobti, CEO & MD, Ranbaxy, said, “The creation of a Daiichi Sankyo Division within Ranbaxy Mexico marks our
first endeavour in creating a dedicated marketing arm for Daiichi Sankyo's portfolio of innovator products. Our
understanding of Latin American markets and local presence pave the way for an efficient and immediate market entry
for Daiichi Sankyo, while priming the channel for the launch of Ranbaxy speciality products in the future.” More
recently Daiichi Sankyo and Ranbaxy, have agreed to commercialize Olmesartan medoxomil, an antihypertensive
discovered by Daiichi Sankyo, and also promote Prasugrel, an antiplatelet co-developed by Daiichi Sankyo and
Eli Lilly and Company (“Lilly”), in Mexico.
With an estimated population of 107 million people, Mexico is Latin America's second biggest market after Brazil.
The annual pharmaceutical market in Mexico is about US$ 10.4 billion and is ranked 11th largest in the world.

ASIA - PACIFIC

CHINA - RANBAXY TRANSFERS STAKE IN RGCL TO HNG CHEMBIO PHARMACY CO. LTD.

Ranbaxy transferred its entire shareholding in Ranbaxy (Guangzhou China) Limited (RGCL) to HNG Chembio
Pharmacy Co. Ltd. (HNG) in December.
RGCL was a joint venture between the Ranbaxy group, Guangzhou Baiyunshan Pharmaceutical Company Limited,
Guangzhou, China and Hong Kong New Chemic, Hong Kong.
The transaction is a part of Ranbaxy's endeavour to develop a new business model for China which entails the
marketing of value-added pharmaceutical formulations and the consolidation of manufacturing operations, for cost
synergies. China continues to be an important market for Ranbaxy and this new approach will create greater value.

JAPAN - RANBAXY DISSOLVES JV WITH NIPPON CHEMIPHAR

Ranbaxy dissolved its joint venture - 'Nihon Pharmaceutical Industry Co. Ltd' (NPI), in Japan in December. This follows
an agreement between the two companies that allows NC to purchase the entire shareholding of its erstwhile partner.
Both companies held equal shares in the JV. Following the transaction, NPI will become a wholly owned subsidiary of
Nippon Chemiphar.
In recent years, the Companies had discussed the evolving generic market scenario and the emerging opportunities,
in Japan. It was amicably concluded, that it would be in the best interest of both companies to develop their generic
businesses independently, for optimal value.
The existing generic products being manufactured and supplied from Ranbaxy's manufacturing plants, in India, will
continue to be supplied to NC, for some time, to enable a smooth transition.
Japan is the second largest Pharma market in the world and is gradually opening up to generic drugs. This provides
many opportunities for both companies to build and consolidate their presence in Japan.

11
 Global Moves
ASIA - PACIFIC

MALAYSIA - FLUHALT CAMPAIGN

Ranbaxy, in collaboration with the Ministry of Health,

Malaysia, launched a 'Prevent and Treat Influenza A
(H1N1) Clinic' Campaign to provide an easy and
affordable access to antiviral treatment for
Influenza A (H1N1) to the public of Malaysia. The
campaign, launched under the umbrella campaign of
the Ministry of Health, Malaysia – ‘Let’s stop H1N1',
was done with private health clinics all across the
country.
Mr Dato' Sri Liow Tiong Lai, Minister of Health,
Malaysia, launched the campaign in Kuala Lumpur.
Other distinguished guests included Dato' Abdullah
Mohd Yusof, Chairman, Ranbaxy (M) Sdn. Bhd.,
From (L-R) Dato' Abdullah Mohd Yusof., Dato' Sri Liow Tiong
Lai, Datuk Dr Rahman Ismail and Mr Jeyabalan Thangarajah
Mr Jeyabalan Thangarajah, ASEAN Director and MD,
during the press conference of the campaign launch. Ranbaxy (M) Sdn. Bhd. and Datuk Dr Rahman Ismail,
MD, Alriz Sdn Bhd – co-promoter of the event.
During the campaign, the participating clinics could
purchase Fluhalt (Oseltamivir Phosphate) manufactured
by Ranbaxy at a significantly reduced price, making it more
affordable for the common people. The participating
clinics could be identified with a sign – 'Klinik Cegah dan
Rawat Influenza A (H1N1)' ('Prevent and Treat Influenza A
(H1N1) Clinic') displayed at their doors.
The campaign attracted more than 1000 clinics (16% of
global number of clinics) from all over the country. A
multilingual website at www.h1n1.net.my was also put in
place to provide necessary information on Influenza A
(H1N1) to the public and also to allow the people to locate
the participating clinics near their respective localities.

Appreciating Ranbaxy's efforts, the Hon'ble Minister of Health, Malaysia, said, “It is praiseworthy that the Company has
brought down the prices of this essential drug to help the common people in this pandemic situation. They have even
gone one-step further to launch this campaign with the private clinics to provide affordable treatment to the public.”

AFRICA

OLMESARTAN TO BE LAUNCHED IN SIX AFRICAN COUNTRIES

Ranbaxy will launch Olmesartan Medoxomil, an antihypertensive originally discovered by Daiichi Sankyo, in six
African countries: Kenya, Mozambique, Nigeria, Tanzania, Uganda and Zambia. The products will be launched under
the brand name Olvance™, as soon as the necessary measures have been completed in each country.
"I am delighted to announce the introduction of Olvance in Africa through Ranbaxy's network," said Mr Takashi Shoda,
President & CEO of Daiichi Sankyo. "This is the first time in Africa that Daiichi Sankyo and Ranbaxy are leveraging
mutual synergies generated through the Hybrid Business Model and we will continue to explore other collaborations
with Ranbaxy that will help deliver our innovative products to the patients throughout the globe", he added.
Commenting on the occasion, Mr Atul Sobti, CEO and M D of Ranbaxy, said, "Ranbaxy has a significant presence in
the African continent. We will utilize our strong business network to bring the innovative medicines of Daiichi Sankyo to
the African people."
Olmesartan Medoxomil is a member of the Angiotensin receptor blocker (ARB) class of antihypertensive medications
that help lower blood pressure by blocking the angiotensin II receptor on the blood vessels and antagonizing the
release of hormone which causes salt retention and increased blood volume. Olmesartan Medoxomil is available in
more than 50 countries worldwide.
®
Ranbaxy launched Olmesartan Medoxomil as Olvance in India in April 2009, followed by the August launch of
Ol-Vamlo™, a fixed-dose combination of Olmesartan Medoxomil with Amlodipine Besylate.

12
Global Moves
INDIA

RANBAXY LAUNCHES A NEW CHEMICAL ENTITY (NCE), LULIFIN (LULICONAZOLE

The Dermatological Product in-licensed from Summit Pharmaceuticals,

Japan, strengthens Ranbaxy’s skin portfolio

Ranbaxy launched a New Chemical Entity (NCE), Lulifin (Luliconazole), in the

Indian Dermatology market. This follows a strategic in-licensing agreement
with Summit Pharmaceuticals International Corporation, Japan (SPI) allowing
Ranbaxy, exclusive marketing rights, for India. The introduction of this NCE,
significantly strengthens Ranbaxy's presence in the Dermatological segment.
Commenting on the development, Mr Sanjeev Dani, Senior Vice President &
Regional Director, Asia & CIS said, “It is well recognized that in the post patent
era, licensing would be the key strategy to bring New Chemical Entities to
India. Dermatology is one of the top priority therapeutic areas for us and we
are pleased to introduce Lulifin in the Indian market. We would be
manufacturing the product in India under license from SPI, Japan.”
Lulifin is a topical imidazole and is indicated for Cutaneous mycoses caused by Tinea pedis, Tinea corporis, Tinea
cruris. Currently, topical imidazoles and allylamines are used for the treatment of Cutaneous mycoses with
disadvantages like long duration of therapy, which leads to poor compliance and a high relapse rate. Clinical trials
conducted by Nihon Nohyaku with Pola Chemical Industries, Inc. (currently Pola Pharma Inc. Tokyo), in Japan and by
Ranbaxy, in India, confirm the at par efficacy with other topical imidazoles but with the added advantage of shorter
therapy duration and once a day application. This greatly improves patient compliance with significantly better
outcomes.
Luliconazole was discovered by Nihon Nohyaku Co. Ltd. (Nihon Nohyaku) and was approved and launched in Japan
in 2005. Based on SPI's licensing know-how and strong network abroad, SPI in-licensed the rights for Luliconazole in
certain territories from Nihon Nohyaku, to expand its reach in overseas markets. In India, SPI has entered into a
licensing agreement with Ranbaxy to market the product exclusively.

WALKING FOR A CAUSE

On World AIDS Day, Ranbaxy organised a WALKATHON to express its solidarity in fighting the struggle against
HIV/AIDS. The event, held in Mumbai on December 1, 2009, was attended by over 2,500 doctors from various
specialities. The event was flagged off at Nariman Point by the Commissioner of Police, Mumbai - Mr D Shivanandan.

13
 Global Moves
INDIA

DF MANUFACTURING SITE AT MOHALI (SEZ) - A NEW FEATHER IN THE CAP

The new Mohali A 41 facility, is located in the heart of the

industrial hub in Mohali, around 250 kms from the capital
of India – New Delhi. The Plant will manufacture products
of international quality at competitive cost. This
manufacturing location has been set up in a Special
Economic Zone, to cater to developed markets like US and
EU.
The manufacturing facility made a beginning in the last
quarter of 2008 after complete qualification and
implementation of Quality Management System. It
currently supports the scale up and exhibit batches of
important drugs. The site also has first-of-its-kind NCE
facility, commissioned within set timelines, with regulatory
approvals for manufacturing of New Chemical Entity – RBX 10017609 (5 mg, 25 mg, 100 mg &
400 mg) for Phase I clinical studies of respiratory drug for India and Europe. The Daiichi Sankyo team recently visited
the manufacturing area, warehouse and quality control labs of the site. They appreciated the facility upkeep, Quality
Systems and the teamwork. The visit concluded with a Tree plantation drive.

The forward looking and contemporary site has implemented many advanced procedures.
Major accomplishments:
• People participation in the design, implementation and monitoring of manufacturing operations and quality
system.
• Temperature monitoring of the RM store, Packing material, Cold storage and FG store, with the help of Wireless
Data Loggers to get continuous monitoring and real time data recording in non-editable format.
• Mobile alert system installed in cold rooms and other unmanned areas.
• Biometry-based Attendance Recording System.
The team at the site is now gearing up for the commercial production in 2010 and have all the synergies lined up for
achieving the organisational goals

14
Honours & Awards
RANBAXY HONOURS SCIENTISTS AND YOUNG BRIGHT SCHOLARS FOR
OUTSTANDING CONTRIBUTIONS IN MEDICAL AND PHARMACEUTICAL RESEARCH

Ranbaxy Science Foundation announced its 21st Annual Research Awards 2008 to Indian Scientists in recognition
of their outstanding research contributions made in the fields of Medical and Pharmaceutical Sciences. The
Foundation also announced its 3rd Annual Science Scholar Awards for the young, brilliant upcoming generation of
scientists.
The Awards were presented by renowned scientist Prof Peter C Doherty (Nobel Laureate) Laureate Professor,
Department of Microbiology and Immunology, University of Melbourne, Australia, at a special function held at the
National Institute of Immunology, New Delhi.
A total of six scientists and five science scholars were awarded.

Six Scientists Honoured with Awards

RANBAXY RESEARCH AWARDS 2008

Medical Sciences – Basic Research
Anindya Dutta, M.D., Ph.D., Byrd Professor of Biochemistry & Molecular Genetics, Professor of Pathology, Jordan
Hall 1240, Box 800733, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA for identifying
several regulators and pathways that normally prevent cells from over-replicating their DNA, and how these molecules
are disrupted in cancers to lead to genomic instability.
Medical Sciences – Medical Research
Dr Inder J Chopra, Distinguished Professor of Medicine, Division of Endocrinology and Metabolism, David Geffen
School of Medicine at UCLA, 900 Veteran Ave., Warren Hall rm. 24-130, Los Angeles, California, 90095 USA, for his
original contributions in developing and characterizing the metabolism of thyroid hormones including nonthyroid
disease effects and its therapeutic implications.
Medical Sciences – Clinical Research
Dr Narmada P Gupta, Professor & Chairman, Department of Urology, All India Institute of Medical Sciences, New
Delhi, India, for his outstanding contributions in advancing the management of various urologic diseases.
Dr Amod Gupta, Professor of Ophthalmology, Advanced Eye Centre, Post Graduate Institute of Medical Education
and Research, Chandigarh, India, for his outstanding contributions in the management of several blinding diseases
and for providing initial evidence for the use of statins in patients with diabetic retinopathy.

15
 Honours & Awards
Pharmaceutical Sciences
Dr G V Madhava Sharma, Scientist F (Deputy Director), Head Organic Chemistry Division III, Indian Institute of
Chemical Technology, Hyderabad, India, for his innovative contributions in developing novel routes for synthesis of
lead molecules in the areas of anti-asthma (PDE-4, ICAM-1 inhibitors), anti-HIV (NNRT inhibitors) and Proton Pump
inhibitors.
Prof Prasad V Bharatam, Professor, Department of Medicinal Chemistry, National Institute of Pharmaceutical
Education and Research NIPER, Punjab, India, for his innovative contributions in designing new anti-diabetic and anti-
malarial lead compounds.

RANBAXY SCIENCE SCHOLARS 2009

Ms Ruthrotha Selvi B, Ph.D. Student, Transcription and Disease Laboratory, Molecular Biology and Genetics Unit,
Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India, for her research work in the area of
Histone arginine methylation and acetylation in global gene regulation, probed by small molecule modulators.
Ms Teena Mohan, Ph.D. Student, Department of Biochemistry, All India Institute of Medical Sciences, New Delhi,
India, for her research work in the area of ‘Developing defensins as a mucosal adjuvant/microbicide with peptide
antigens of HIV’.
Ms Hardeep Kaur, Senior Research Fellow, Microbial Physiology and Genetics, Institute of Microbial Technology,
Chandigarh, India, for her research work in the area of ‘Glutathione degradation pathway and identifying a novel
CysGly specific dipeptidase in S.cerevisiae- Dug1p. Glutathione (GSH) is considered as a major cellular redox buffer
and is present in almost all eukaryotic systems’.
Mr Gaurav Vadnerkar, National Doctoral Fellow of AICTE, Department of Pharmaceutical Chemistry, Poona
College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune, India, for his research work ‘Synthesis, Kinetic
Studies and Pharmacological Screening of Prodrugs for Colon-specific Drug Delivery in Inflammatory Bowel Disease’.
Mr Alok Nahata, National Doctoral Fellow - AICTE, Department of Pharmaceutical Sciences, Doctor Hari Singh
Gour Vishwavidyalaya, Sagar, India for his research work on ‘Memory boosting effects of Canscora decussata Schult
in albino rats’.

Five Young Scholars Awarded

16
Honours & Awards
RSF SYMPOSIUM

Ranbaxy Science Foundation organized its XVI Annual

Symposium on ‘Emerging Frontiers in Immuno-genomics of
Infectious Diseases’. Prof Peter C Doherty (Nobel Laureate)
Laureate Professor, Department of Microbiology and
Immunology, University of Melbourne, Australia was the
Chief Guest and the keynote speaker at the event. Eminent
scientists from India and abroad deliberated on emerging
frontiers in the field of immune-genomics in respect of the
parasitic, bacterial, fungal and viral infectious diseases,
which has great potential for improving human health and
paving the way for future research in the area.

RANBAXY AWARDED FOR ‘OUTSTANDING CONTRIBUTION TO THE PHARMACEUTICAL INDUSTRY’

Mr R Ganesh, Director, Trade Finance, received the award

on behalf of Ranbaxy for 'Outstanding Contribution to the
Pharmaceutical Industry' from Mr Anand Sharma, Hon'ble
Union Minister for Commerce & Industry, Govt of India,
during an event organised by Pharmexcil.

HONOUR FOR RANBAXY DEWAS

During the celebrations of the Foundation Day of
Madhya Pradesh, the Hon'ble Chief Minister of Madhya
Pradesh – Mr Shivraj Singh Chauhan, visited Dewas for
an exclusive interaction with Industry delegation and
felicitated Ranbaxy Dewas for its significant contribution
in the field of Pharmaceutical manufacturing and being
one of the largest exporters from the state. Mr Rajneesh
Mitra, Senior Manager, Public Relations, Ranbaxy
Dewas, received a trophy along with a certificate from
the Hon'ble Chief Minister.

17
 Financial Update
RANBAXY REPEATS STRONG OPERATING PERFORMANCE
FY 2009 PROFIT BEFORE TAX OVER RS. 1,000 CRORES; GLOBAL SALES AT RS. 7,344 CRORES
Consolidated Financial Performance for twelve months ended December 31, 2009
• Global sales were USD 1519 Mn (Rs. 73,441 Mn) [FY’08: USD 1,667 Mn; Rs.72,555 Mn]
• Profit Before Tax was USD 209 Mn (Rs. 10,098 Mn), a margin of 14% to sales [FY’08: USD (320) Mn; Rs. (15,000) Mn]
• Profit After Tax was USD 64 Mn (Rs. 3,107 Mn), a margin of 4% to sales [FY’08: USD (198) Mn; Rs. (9,349) Mn]
Consolidated Financial Performance for the quarter ended December 31, 2009 (Q4’09)
• Global sales were USD 482 Mn (Rs. 22,699 Mn), a growth of 25% over Q4’08 [Q4’08: USD 387 Mn; Rs.19,096 Mn]
• Profit Before Tax was USD 194 Mn (Rs. 9,389 Mn) [Q4’08: USD (242) Mn; Rs.(11,464) Mn]
• Profit After Tax was USD 54 Mn (Rs. 2,620 Mn) [Q4’08: USD (142) Mn; Rs. (6,798) Mn]
The effective tax rate is higher during the quarter, and the year, due to accounting treatment of taxes on unrealised profits, and partial impairment of deferred tax assets in accordance with
Accounting Standard 22 of Indian GAAP. Such tax adjustments are non-cash in nature, and are expected to be normalised over the coming quarters.

GLOBAL REGION-WISE SALES FOR THE YEAR 2009: US $ 1519 Mn

US $ Mn
Asia
86
RoW (Rest of world)
441
397
API

Europe
269 214
112
North America
CIS

Commenting on the business results for the quarter, Mr. Atul Sobti, CEO & Managing Director, Ranbaxy, said, “We realized various
opportunities, while continuing to manage key challenges. Good revenue growth in most key geographies, launch of two First-to-File (FTFs)
in USA, and continued cost containment, has ensured consistent quarter-on-quarter improvement in performance. The Company ended
the year with strong business and financial performance, and over achieved on the guidance given for the year.”
Key Highlights/Developments:
• Profitability improved in Q4’09 over previous year, as well as trailing quarter.
• Despite continued challenges in the US market, the Company successfully launched two FTF products with exclusivity viz., Valacyclovir
and Oxcarbazepine Suspension during Q4’09, and Sumatriptan earlier in the year.
• Due to strengthening of the Indian Rupee, gains on account of Mark-to-Market (MTM) translation losses booked earlier in the year were
substantially reversed.
• The Company rolled out project “Viraat”, aimed at strengthening its leadership position in the market.
• The Company’s facility at Paonta Sahib received GMP approvals from MHRA-UK, TGA-Australia and WHO, Switzerland. The
Batamandi facility at Paonta Sahib was approved by PMDA-Japan.
• The Company announced the commencement of Phase-III clinical trials for its new Anti-malaria combination drug, Arterolane Maleate
+ Piperaquine Phosphate, in India and Thailand.
• Realising synergies between Ranbaxy and Daiichi Sankyo (DS), the Company launched DS research products Olmesartan in India, and
Raloxifene in Romania. The Company has set up a new division to market DS products in Mexico. Ranbaxy will also launch Olmesartan
in six African countries
• The Company made its first USFDA filing from its new facility located at its SEZ in Mohali.
• In Q4’09, the Company received a Warning Letter from the USFDA for its facility at Gloversville, NY, USA. The Company has
responded to the observations of the regulator.

Outlook
During 2010, Ranbaxy expects to achieve sales of approximately Rs. 78 Bn (USD 1.7 Bn),
as against Rs. 73.4 Bn in 2009, a growth of 6%; and PAT of approx Rs. 4.6 Bn (USD 100 Mn), as
against Rs. 3.1 Bn in 2009, a growth of 48%. This estimate is based on the assumptions of
exchange rate of USD:INR of 46.00.

18
Heart of Business
CANADA - MAY DAY EVENT
Ranbaxy Pharmaceuticals Canada Inc. (RPCI) participated as a Special Events
Sponsor in a May Day event in Toronto. Many Canadian colleagues were present
at this special event held at Colonel Samuel Smith Park, in Southern Etocicoke
(Toronto). The event was hosted by The Gatehouse® - a charity that runs with a
mission to eliminate child abuse and to provide community responses to those
whose lives have been impacted by abuse. The Gatehouse® strongly believes in
the need for community support in the aftermath of child abuse. “A safe and
comfortable environment like The Gatehouse® offers people a comforting place
where they can feel supported,” said Paul Drake, President, RPCI. “They provide
both a safe place for children to disclose abuse to the police and child welfare
personnel as well as support services for adults whose lives have been affected by
childhood abuse. As a company, we are privileged to offer our sponsorship to this
worthy charity,” he added. The total donation for the event amounted to
US $15,000 and Ranbaxians were pleased to play a supporting role in achieving
this level of contribution.

SOUTH AFRICA - SPREADING CHRISTMAS CHEER

The Ranbaxy South Africa team added cheer to the little

faces when they recently held a Christmas party for the
children at Centurion Hospice. Santa Claus lit up the faces
of the children with his gifts and presents.
The children, most of whom suffer from HIV and other life
threatening diseases, performed a touching concert for the
team. Ranbaxy South Africa has been undertaking various
initiatives for these children such as holding Easter parties,
Spring Day etc.
The Company also holds an annual raffle and collects
money to carry out these initiatives besides sponsoring the
nursery school requirements of the children for the year.
The team collected R50 300.00 for this worthy cause in
November 2009.

FRANCE - LA PARISIENNE' RACE

Ranbaxy France participated in the annual 'la Parisienne' race this year
too. Eleven women ran in this race which is organized every year, to
raise funds for research on the prevention and treatment of breast
cancer. More than 15,000 women participated in the race, an event
full of energy and excitement, for a noble mission.

INDIA - SPREADING AWARENESS ON SWINE FLU

All Ranbaxy Community Healthcare Society (RCHS) units launched

an extensive campaign on Swine Flu pandemic at Paonta Sahib,
Dewas, Gurgaon and Beas units with an aim to educate the
community about the nature of disease, mode of spread and
preventive measures to allay anxiety and fear caused due to
increasing number of deaths as being reported by the media.
A number of activities like leaflet distribution, lectures, discussions,
essay competitions and demonstrations on hand washing were held
to disseminate important information about the disease, especially
among the school students.

19
 Heart of Business
INDIA - DEWAS BLIND SCHOOL ACTIVITY

The employees at Ranbaxy Dewas, recently visited 'Madhya

Pradesh Drishtiheen Kalyan Sangh', an organization that
provides boarding school facility to sightless girls. There are
around 45 girls studying in the school where they are also
given vocational training besides basic education.
Ranbaxy Dewas, with the help of Ranbaxy Community
Healthcare Services (RCHS), organized a health check-up
camp in the school and provided them with essential
medicines. The Company also donated a few musical
instruments to the school.

WORLD AIDS DAY RCHS

Ranbaxy Mohali observed the ‘World AIDS Day’

through a unique musical road show organized in
collaboration with Fortis, Mohali. The artists from
Fortis sang songs and ‘Qawaalis’, whose lyrics were
interspersed with messages on AIDS awareness. They
were also accompanied by a team of Medical experts
who delivered a short talk on the subject. The theme
for this year’s World AIDS Day was – ‘Leadership’ with
a slogan - ‘Stop AIDS, Keep the Promise’.
All RCHS healthcare units also organized special
programmes to promote AIDS awareness.
A number of exhibitions, puppet shows, quiz
competitions, film shows including
distribution of educational material on
HIV/AIDS were conducted on the day. Group
discussion followed by a question and answer
session was also held for the youngsters to address
their misconceptions about the disease.

INDIA - CHOLERA PREVENTION CAMP, MOHALI

The RCHS team at Mohali played an important role in controlling the
spread of Cholera at Mohal village, close to Ranbaxy’s plant at Mohali. The
village has a population of about 11,000. It was after reporting of 38 cases
of acute diarrhoea in June, which raised suspicion of the suspected
outbreak of Cholera. Ranbaxy’s health team at Mohali investigated the
source of infection and took appropriate measures to contain the outbreak,
using scientific principles of epidemiology. The disease was also notified
with the government heath authorities. A massive awareness campaign
about the signs and symptoms of Cholera including health education on
personal hygiene, environmental sanitation and disposal of excreta was
also launched. The professional skills and rapid response shown by Ranbaxy’s health team was very well appreciated
by the health authorities and community.

INDIA - WORLD ENVIRONMENT DAY, TOANSA

The employees at Toansa observed ‘World Environment Day ’ on
5th June, with great enthusiasm. This year’s UNEP theme was
‘Your Planet needs You! Unite to Combat Climate Change’. The
employees observed the day in the same spirit when more than
200 of them participated in a mass ‘Plantation Drive’ with 300
saplings of different varieties being planted.

20
Happenings

Mr Sridhar Subramanian from Ranbaxy China with Ms Nirupama Rao, (Center)

Ex-Ambassador of India to China, during her farewell before she assumed the office as Foreign Secretary,
Govt of India

(Left) US Ambassador to India, (Left) Dr Bob Davies (Minister for Trade &
H. E. Timothy J Roemer Industry, South Africa)

Mr Anand Sharma, Commerce Minister of India during the recently concluded CII mission to South Africa

21
 Happenings
A high level delegation led by H.E. Wittaya Kaewparadai, Public Health Minister, Thailand & Thailand Ambassador
to India H. E. Krit Kraichitti at Ranbaxy Corporate Office

Mr Daniel Boda,
President Romania National
Medicine Agency with the
Ranbaxy Senior Management
at the Corporate Office

Ministry of Health, Bahrain, led by Dr Mohammad Nasser, Director of Pharmacy Control and
Ms Rehab, Chief Pharmacist of Salmanya Hospital along with Mr Nandakumar, Regulatory Manager,
Gulf Pharmacy (Ranbaxy's partner in Bahrain) at Ranbaxy's manufacturing facility in Dewas, India

22
 February 27, 2010
February 26, 2010

Newstrack

THE FINANC January 20,

IAL EXPRESS 2010

Managing Editor: Ranbaxy World is edited and published by Ranbaxy World is also available on our website.
Ramesh Adige, Global Corporate Communications, www.ranbaxy.com
President - Corporate on behalf of Ranbaxy Laboratories Limited.
Affairs & Global
Corporate Corporate Office:
Communications, Ranbaxy Plot No. 90, Sector 32, Gurgaon, Haryana, India.
Tel: 91-124-4135000.
e-mail: corporate.communications@ranbaxy.com